New Antibody-Drug conjugate KIVU-107 enters first human trials for Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…
Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC